COMPUMEDICS LIMITED — Investor Presentation 2026

Mar 24, 2026

Corporate Presentation March 2026

==> picture [348 x 54] intentionally omitted <==

==> picture [529 x 105] intentionally omitted <==

==> picture [432 x 105] intentionally omitted <==

Business Snapshot

==> picture [529 x 73] intentionally omitted <==

Compumedics (ASX: CMP) is a leading global medical technology company focused on sleep, neurological disorders and ultrasonic brain blood flow monitoring.

Technology Australia based, developer/leader in with wholly owned Long track record, Compumedics’ offices in the USA, having been respective end Germany, France, founded in 1987 markets, with over Austria and Korea and listed on the 25,000 systems and a network of ASX since 2000 installed worldwide 100+ distributors to date globally

==> picture [59 x 60] intentionally omitted <==

==> picture [341 x 112] intentionally omitted <==

----- Start of picture text -----

Generated $31m of
Global team revenue in H1
comprised of FY26. Revenue
~180 people $31M guidance of up to
across 6 A$70M and EBITDA
countries of A$9M in FY26
----- End of picture text -----

Compumedics has a number of leading market positions

B2B business model with leading blue-chip customer base

==> picture [38 x 37] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Australian Japan #1 Sleep and neuro #1 Sleep and neuro diagnostics diagnostics supplier supplier

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

Germany #1 TCD Supplier

USA Sleep diagnostics device supplier and emerging #3 supplier for neurological monitoring devices

China

Sleep diagnostics device supplier to premier facilities (and #1 TCD supplier)

• Compumedics sells directly to end-user customers in Australia, USA, France and Germany and through its network of more than 100 distributors to all other parts of the world

• Key customers include hospitals, doctors/clinics, universities and research organisations

==> picture [379 x 68] intentionally omitted <==

Executive Summary

==> picture [529 x 73] intentionally omitted <==

Record H1 performance with accelerating recurring revenue and improving earnings quality

==> picture [562 x 154] intentionally omitted <==

----- Start of picture text -----

Record Sales Orders Record Sales Revenue
$34.9M $31.0M
Up +6% on H1 FY25 Up +32% on H1 FY25
Up +20% on H1 FY24 Up +17% on H1 FY24
----- End of picture text -----

==> picture [41 x 10] intentionally omitted <==

----- Start of picture text -----

EBITDA
----- End of picture text -----

==> picture [251 x 112] intentionally omitted <==

----- Start of picture text -----

$3.1M
Up +343% on H1 FY25
----- End of picture text -----

Platform Momentum & Revenue Mix Shift

Core Priorities

Growth Drivers

• SaaS scaling driving recurring revenue growth , with increasing contribution from software, consumables and services

• MEG pipeline progressing , with orders and installations supporting revenue visibility into FY26– FY27

• Installed base of ~25,000 systems underpinning recurring consumables, upgrades and service revenue

• Business model shifting toward higher-margin, recurring revenue streams , improving visibility and earnings quality

• Execute U.S. Somfit rollout targeting the largest global sleep diagnostics market

• Scale recurring revenue across SaaS, consumables and connected diagnostic services

• Deliver MEG order book and support transition to clinical adoption

• Expand installed base utilisation to drive recurring revenue and customer lifetime value

• Drive operating leverage through cost discipline and improving product mix

• Large and underpenetrated sleep diagnostics market , with 80–90% of cases undiagnosed globally

• Shift to home sleep testing (HST) driving higher volumes and SaaS adoption

• U.S. market expansion representing a ~$100m–$200m SaaS opportunity over the next 2 years

• MEG commercialisation as a high-value neurodiagnostic platform with limited competition

• Improving revenue mix toward recurring streams supporting margin expansion and scale

• Clear pathway to earnings growth and valuation rerating as recurring revenue scales and U.S. execution improves

==> picture [529 x 73] intentionally omitted <==

Board and Management

Strengthened leadership and governance to support the next phase of growth

Strengthened Board Renewal Execution Systems and Performance Executive Team Capability Controls Focus 1. Targeted hires 2. Chris Barys was 3. Broader operating 4. Continued 5. Leadership have strengthened appointed as a capability now investment in priorities aligned to leadership across U.S.-based Nonsupports scale, systems, reporting SaaS growth, MEG key functions, with Executive Director delivery discipline and processes to execution, U.S. a further senior in H1 FY26, and accountability strengthen performance, U.S. commercial strengthening across the Group, transparency, innovation and appointment to board capability, including the operating margin delivery. support execution governance and build-out of highly discipline and discipline and U.S. market skilled MEG scalability across commercial scale perspective. manufacturing the Group. in the U.S.. capability.

==> picture [348 x 54] intentionally omitted <==

H1 FY26 Financial Performance

==> picture [960 x 359] intentionally omitted <==

H1 FY26 Financial Results

Compumedics is building earnings momentum through revenue growth, recurring revenue expansion & cost discipline

Sales Orders ($M)

==> picture [274 x 174] intentionally omitted <==

----- Start of picture text -----

Record sales orders H1 FY26 up +6% YoY
34.9
32.8
29.2
17.4 17.8
H1 FY22 H1 FY23 H1 FY24 H1 FY25 H1 FY26
----- End of picture text -----

Sales Revenue ($M)

==> picture [168 x 9] intentionally omitted <==

----- Start of picture text -----

Record sales revenue H1 FY26 up +32% YoY
----- End of picture text -----

==> picture [252 x 151] intentionally omitted <==

----- Start of picture text -----

31.0
26.4
23.5
19.2
18.0
H1 FY22 H1 FY23 H1 FY24 H1 FY25 H1 FY26
----- End of picture text -----

USA Revenue ($M)

==> picture [274 x 175] intentionally omitted <==

----- Start of picture text -----

USA revenue down -5% YoY
8.0
7.5
4.4
4.0
3.1
H1 FY22 H1 FY23 H1 FY24 H1 FY25 H1 FY26
----- End of picture text -----

Somfit & SaaS Sales Orders ($M)

==> picture [274 x 176] intentionally omitted <==

----- Start of picture text -----

Record Somfit & SaaS Revenue: 13% of total revenue (8% H1 FY25)
4.5
2.8
2.0
1.0 1.0
H1 FY22 H1 FY23 H1 FY24 H1 FY25 H1 FY26
----- End of picture text -----

EBITDA ($M)

EBITDA: $3.1M with margin expansion supported by operating leverage and increasing contribution from recurring revenue

==> picture [266 x 130] intentionally omitted <==

----- Start of picture text -----

3.1
2.2
1.2
0.7
H1 FY22 H1 FY23 H1 FY24 H1 FY25 H1 FY26
-4.8
----- End of picture text -----

Key Takeaways

Compumedics Performance

• CMP produced YoY growth across all major financial metrics in H1 FY26 (except U.S. revenue)

• H1 FY26 performance provides a platform for material earnings growth in FY26

Market Overview & Performance

• Structural growth in sleep, neurology and brain imaging markets

• Growing shift to home-based diagnostics and SaaS-enabled platforms

• MEG & TCD gaining momentum in high-value neurodiagnostics

• Asia & Europe delivered strong H1 momentum

• Compumedics increasingly exposed to higher-value, technology-led and recurring revenue segments

H1 FY26 Financial Performance

Compumedics produced YoY growth across all major financial metrics in H1 FY26

Financial Performance

$M	**H1 FY24A **	**H1 FY25A **	H1 FY26A	FY26F
Sales Orders	29.2	32.8	34.9	75.0
Growth YoY	75%	12%	6%	+18%
Revenue Reported	26.4	23.5	31.0	70.0
Growth YoY	38%	-11%	32%	+37%
Gross Profit	14.5	12.8	16.0	37.8
Gross Margin	55%	55%	51%	54%
EBITDA	2.2	0.7	3.1	9.0
EBITDA Margin	8%	3%	10%	13%

FY25 Highlights:

• Record Sales Orders: $34.9M, up +6% YoY

• Record Revenue: $31.0M, up +32% YoY

• Gross Profit: $16.0M, up +25% YoY

• EBITDA: $3.1M, margin increased to 10%, driven by record sales and progress on a $2 million per annum cost reduction program to lift operating leverage and support margin expansion

Key Drivers:

• Recurring revenue accelerating as SaaS and annuity growth lifts revenue quality and visibility

• MEG momentum building with new orders and milestone revenue supporting the H2 and FY27 pipeline

• Asia and Europe driving growth with steady ANZ performance

• U.S. reset in progress to sharpen execution, align costs and support H2 recovery

FY26 Guidance:

• Revenue: $70.0M (+37% YoY)

• EBITDA: $9.0M (13% EBITDA Margin)

Business Model and Revenue Diversification

Diversified revenue base across multiple geographies and segments

Geography

Segment

USA:

Sleep & SaaS:

• High-end PSG systems + rapidly scaling Somfit SaaS platform

• Core growth driver with sleep and neuro acceleration

Europe:

• New Somfit and Sleep opportunities, neuro wins and DWL rebound

Asia:

• Clinical-grade, cloud-connected, and built for the shift to home sleep testing

Neuro Monitoring & Research:

• World-first wireless EEG (Okti) and MEG brain analysis systems

• Trusted by neurologists & researchers tackling epilepsy, autism, and brain injury

• China MEG expansion and large sleep distribution contracts

Australia:

Bloodflow & TCD:

• DWL systems for real-time brain blood flow monitoring

• Next-gen robotic TCD opens door to AI-driven stroke diagnostics

• Somfit pharmacy partnership driving growth

Latin America & Middle East:

Consumables & Customer Care:

• Recurring revenue from electrodes, disposables, and support

• Targeted distributor expansion

• Installed base-driven model supporting recurring consumables, and service revenue

==> picture [372 x 189] intentionally omitted <==

----- Start of picture text -----

13%
Key
Asia
H1 FY26
48%
18% Sales U.S
Orders: Europe
$34.9M Australia
21%
----- End of picture text -----

==> picture [431 x 189] intentionally omitted <==

----- Start of picture text -----

12%
32% Clinical
diagnostics,
6% 13% Somfit & Key
Nexus 360
Sleep
H1 FY26
Sales 45% Brain
Orders: Bloodflow & TCD
$34.9M Consumables
13% clinical
monitoring,
10% research, 37%
14% MEG
----- End of picture text -----

==> picture [348 x 54] intentionally omitted <==

Segment Performance & Outlook

==> picture [960 x 359] intentionally omitted <==

Segment Overview & Performance

Compumedics’ technology is focused on the fast growing, high value sleep diagnostics market and the associated fields of neuro-diagnostics and brain research

Sleep & SaaS ($M)	H1 FY25	H1 FY26	Neuro Monitoring & Research ($M) Sales Orders Revenue Reported YoY% (19%) +3%	H1 FY25	H1 FY26	YoY%
Sales Orders	19.4	15.7		7.6	12.8	+70%
Revenue Reported	11.6	12.0		6.2	13.2	+114%

• U.S. launch of Somfit HST with $3M+ in revenue and $10M pipeline

• Somfit & SaaS revenues to approach 50% of Sleep revenues by FY28

• $24M 4-year with sleep diagnostics distributor in Asia

• $3M 5-year pharmacy channel agreement signed with Philips in AU

• MEG System at TJNU successfully installed in FY24

• $15M in new MEG systems to be reported in FY26 ($5M FY24 | Nil FY25)

• Scalable global opportunity as MEG indications expand

• Okti wireless EEG gaining traction in neurology clinics

• Recurring revenue expected to scale materially, supporting margin expansion and earnings quality

Bloodflow & TCD (DWL) ($M)	H1 FY25	H1 FY26	YoY%
Sales Orders	2.0	2.1	+4%
Revenue Reported	1.9	1.8	(2%)

Service & Supplies (Recurring) ($M)	H1 FY25	H1 FY26	YoY%
Sales Orders	3.9	4.2	+9%
Revenue Reported	3.8	4.0	+4%

• Recovery underway post-China regulatory delays

• AI robotic TCD development at commercialisation stage

• Targeting stroke, TBI, and neuro ICU with autonomous probe tech

• Partner discussions active to accelerate go-to-market

• Steady annuity-style revenue from global installed base

• Supporting growing SaaS client base with hardware and disposables

• Positioned for incremental margin improvement from scale

• Enables stickiness and recurring value from broader platform

Sleep & SaaS

==> picture [529 x 73] intentionally omitted <==

SaaS-Driven Sleep Diagnostics Leadership: High-Growth Momentum, Scalable Model, Global Traction

Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity
Sleep: Clinical Diagnostics	32%	• Strong growth from installed base of 25,000+ system • Market share of 30–40% in high-end sleep diagnostics • Long-term partnership with Philips to drive recurring sales • Global channel scale and 35+ years of sleep R&D		• World leader in sleep diagnostics hardware • Comprehensive offering from full PSG systems to portable solutions • Trusted by hospitals, sleep labs, and specialists globally	Grael: Full PSG systems for clinical sleep testing
Somfit & Nexus 360 SaaS	13%	• H1 FY26 revenue $4.5M (up +61% YoY) • $3M agreement with Philips AU • U.S. launch: $3M revenue to date with Somfit D >$10m early pipeline post-FDA • Targeting 100K+ Somfit units over 5 years • Somfit & SaaS to reach ~50% of Sleep revenue by FY28	• USA HST market growing ~25% p.a., underpinned by 60M to 80M undiagnosed Americans • U.S. HST opportunity of ~$100–200m SaaS revenue over the next 2 years • Upside: ~$250M U.S. reimbursement, ~$1B global reimbursement • Consumer health potential ~$1B to $10B with tech partners • Rapidly scaling cloud-based platform • Enhancing device connectivity, monitoring, and remote diagnostics • Recurring revenue stream with strong margin profile Somfit / Somfit Pro:Wearable diagnostic devices Nexus 360: Web-based lab & patient management

Neuro Monitoring & Research

Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction

Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction	Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction	Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction	Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction	Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction	Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction
Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % H1 FY26 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 13% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 10% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research
MEG	14%	• H1 FY26 MEG revenue: $6.5M • $15M orders for delivery in FY26 • TJNU China site now live, three systems in development, and two new orders for FY27 • Strong multi-year pipeline supporting growth visibility		• Expansion into paediatric MEG lifts near- term opportunity to ~$120M p.a. • High-growth MRI alternative • Long-term upside: OrionMEG® LifeSpan could scale to ~$13.6B if adoption follows MRI trajectory • Expanding in U.S., EU, and China with major centres	Orion Lifespan MEG:Superior functional imaging with unmatched temporal resolution

==> picture [529 x 73] intentionally omitted <==

Blood flow & TCD (DWL)

AI-Driven TCD Innovation: Commercial Momentum in a $12B Stroke Market

Example Products / Solutions (Not Exhaustive)

• % H1 FY26 Example Products / Solutions

• Business Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity (Not Exhaustive)

• Bloodflow & TCD (DWL) • H1 FY26 revenue of $1.8M (typically ~$3M) with growth resuming post-China • • Positioned to disrupt a $12B+ global

• regulatory resolution Positioned to disrupt a $12B+ global stroke diagnostics market with realstroke diagnostics market with real-

• • time, non-invasive blood flow imaging Relaunch of Ez-Dop targeting premium time, non-invasive blood flow imaging hospital market •• Robotic AI-enhanced TCD offers scalable Robotic AI-enhanced TCD offers scalable DWL AI Robotic TCD

• • point-of-care solution with minimal Prototype: Robotic TCD platform advancing toward point-of-care solution with minimal

• 6% commercialisation within 12–24 months operator dependencyoperator dependency Portable module that supports use in various

• •

• • • Compumedics DWL has a strong brand positions. Targeting large unmet needs in stroke, Compumedics DWL has a strong brand presence in neurology and neurocritical

• TBI, and neuro ICU markets presence in neurology and neurocritical care globally care globally

• • Strategic partner discussions underway to fast-track commercial deployment

Service & Supplies (Recurring)

High-Margin Recurring Revenue Powering Platform Stickiness and Scale

Business % H1 FY26 Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity	Business % H1 FY26 Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity
Service & Supplies – Recurring (NeuroMedical Supplies)	14%	• H1 FY26 revenue of $4.0M, underpinned by global installed base • Strong annuity-style revenue stream supporting enterprise-wide recurring model • Supply chain optimised for scalable throughput and cost efficienc • Expansion of hardware and support aligned to growing SaaS install base		• High-margin, predictable revenue stream supporting SaaS lifecycle value • Somfit D unlocks large-scale disposable opportunity linked to 100K+ device units • Consumables model increases customer lifetime value and retention across modalities • Platform enables leverage into broader wellness and diagnostics services ecosystem • High-margin recurring revenue stream supporting visibility, operating leverage and earnings quality • Consumables model increases customer lifetime value and retention across modalities • Platform enables leverage into broader wellness and diagnostics services ecosystem

Example Products / Solutions (Not Exhaustive)

Okti® Child Disposable Backpack Wearable, single-use EEG harness AutoRep Electronic Pipetter High-precision lab consumable for fluid management

==> picture [85 x 90] intentionally omitted <==

==> picture [348 x 54] intentionally omitted <==

Investment Case

==> picture [960 x 359] intentionally omitted <==

Investment Case

==> picture [529 x 73] intentionally omitted <==

Positioned for scalable growth and earnings uplift through recurring revenue and U.S. expansion

Established global leader in sleep and neurodiagnostics

Investment Highlights

• Established global platform with ~25,000 installed systems across 50+ countries

• Transition to recurring revenue model driven by SaaS, consumables and services

• Large underpenetrated markets with 80–90% of sleep disorders undiagnosed globally

• Significant U.S. opportunity in home sleep testing (~US$100–200M SaaS potential)

• 1 Long-standing clinical presence with a recognised position across sleep and brain health diagnostics

Diversified platform across core diagnostic verticals

• 2

• Exposure across sleep, neurodiagnostics and brain monitoring, supporting multiple growth pathways

Significant structural growth opportunity

• 3

• Large, underpenetrated markets with strong tailwinds, particularly in U.S. home sleep testing

• High-value MEG platform with limited competition and global pipeline

• 4

Leading market positions in core markets

• 1 in Australia for sleep and neuro diagnostics supplies with ~80% market share

• Improving earnings quality as revenue mix shifts and operating leverage increases

Blue-chip customer base

• 5

• Supported by multiple channels to market e.g. Philips, National Institute of Health (USA), The Mayo Clinic (USA), NASA (US) etc.

Proprietary technology and sustained innovation

Technology & Growth Pipeline

• Somfit platform scaling as a SaaS and consumables-driven recurring revenue engine

• Somfit D rollout in the U.S. targeting fastest-growing segment of sleep diagnostics

• 6

• Company-developed platforms supported by ongoing R&D investment and differentiated IP (~12% of revenue p.a. dedicated to R&D into new products / IP)

Scalable global operating footprint

• 7 Manufacturing, distribution and partner networks across key markets supporting efficient expansion

• Orion LifeSpan MEG progressing from research to clinical adoption

• AI-enabled robotic TCD expanding DWL capability and product differentiation

Expanding recurring revenue base

• 8 Increasing contribution from SaaS, consumables and services improving revenue visibility and quality

• Expansion into adjacent verticals including pharma, cardiology and research

• 9

Clear re-rating catalysts

• U.S. scaling, recurring revenue growth and MEG execution support valuation upside

• Ongoing R&D investment supporting product innovation and long-term growth

10

Experienced leadership with deep domain expertise

• Long-tenured management team with strong industry knowledge and execution capability

Breakout Growth Platforms

Somfit ® SaaS

OrionMEG®

Somfit ® SaaS – $6.7M (+49%), FDA cleared,

• 700k studies, $10M+ U.S. pipeline; Philips Pharmacy Strategic Partnership; Resmed Major Client; Major Deals: Big Pharmaceutical Co’s & related Contract Research Organisations.

• OrionMEG ® – 3 systems in FY26 (~$15M revenue), $30M sales in start-up phase (China alone) U.S. entry underway; Independent UCSD validation confirming global leadership status.

• Nexus 360 ® SaaS – >800K studies, expanded enterprise workflows.

• Neuroscan®/OKTI ® – Revenue doubled, CURRY ® sales +15%.

• DWL ® – FDA/EU MDR approved EZ-Dop ®, AI Robotic TCD in development.

• OrionMEG®: ~$13.6B (10% MRI-equivalent adoption)

• Renewed CMP Board to Access Market.

• Somfit ® SaaS: USA reimbursement market ~$250M – growth 25% PA - CMP fastest growing AI Sleep (HST/SaaS).

• Global reimbursement: ~$1B.

• Consumer potential: $1–10B (Apple/Google/Amazon partnerships)- Renewed CMP Board to Access Market.

• Alpha Trace ® – €1M sales, Kepler Clinics contract.

H1 FY26 Highlights - At a Glance

H1 FY26 Highlights - At a Glance

Expansion Strategic $4.5M 13% >$10M into Pharma Deals Somfit© & SaaS Of total company Somfit D • $2m initial orders from • $3m PA Philips revenue (up from revenue pipeline post two global pharma • Top Tier U.S. IDTFs $2.8m in H1 FY25) U.S. launch & FDA approval • companiesFurther trials expected • Global leading Somfit©

• Global leading Somfit© SaaS Pharma CRO and big Pharma

• Further trials expected FY28

Regulatory Scientific Broader Business Milestones Validation Progress

Positioned for further FY26 Growth

==> picture [11 x 8] intentionally omitted <==

==> picture [17 x 17] intentionally omitted <==

==> picture [9 x 7] intentionally omitted <==

• Approvals: Brazil, • 3 peer-reviewed Colombia, Hong publications Kong, Singapore •

• Total over 770,000 Somfit© and NEXUS360© SaaS studies

• Somfit SaaS secures 75% AU HST pharmacy market

• More in progress to

• • U.S. Somfit© Pro U.S. strengthen adoption FDA in process for early ‘26FY

• Somfit© expansion, product launches and new market entry

==> picture [33 x 33] intentionally omitted <==

==> picture [34 x 34] intentionally omitted <==

==> picture [45 x 33] intentionally omitted <==

==> picture [24 x 25] intentionally omitted <==

U.S. Market

Validation

Innovation Edge

$30M

Launch in Six Compumedics FY26 MEG labs for total USA as the world’s largest of about $30M in MEG market, will now revenues, in bolster CMP MEG progress China alone in China, the world’s fastest growing market

• “Leading-edge OrionMEG© LifeSpan dual whole-head MEG system from Compumedics

World-first OrionMEG© LifeSpan:

  - Unique dual-helmet child/adult

• is truly a state-of-the-art MEG system.” ‘25: Prof. Mingxiong Huang UCSD Dep. Rad.& Dep. Elect. & Comp. Eng., CoDirect. MEG Centre, Scientist & Physicist VA San Diego (ASX: CMP: 30 Sep25)

• Virtual 100% coolant recycling 24/7 operation

• CURRY MEG s/w years ahead of competitors

• Total non-invasive technique

Positioned for FY26 Growth

Manufacturing

Board

==> picture [36 x 46] intentionally omitted <==

Growth

Strengthened

==> picture [9 x 8] intentionally omitted <==

Plan to launch latest OrionMEG© LifeSpan USA, China

NED MEG Major Factory expansion Strategic Deal and MSR installed Laser Focus

Positioned for Transformational Growth & Re-Rating

Why Invest Now

• Compumedics currently trades at ~A$0.32 per share, implying a market capitalisation of approximately $60-$70 million and enterprise value of $70-$80 million.

• This equates to 1-1,1x FY26 revenue and 8-9x FY26 EBITDA

• On ASX metrics , Compumedics sits around the lower end of domestic small-cap healthcare technology multiples, with Australian emerging healthcare companies typically trading below comparable U.S. peers.

• Despite this progress , Compumedics remains well below global med-tech peer valuations, particularly in the U.S., where revenue multiples are typically 4x to 8x, supporting a clear re-rating opportunity.

Valuation Gap

Compumedics’ Valuation Gap

==> picture [239 x 181] intentionally omitted <==

----- Start of picture text -----

$
Curent Share Price Intrinsic Value
Valuation Gap
----- End of picture text -----

==> picture [417 x 185] intentionally omitted <==

----- Start of picture text -----

8x revenue
6x revenue
4x revenue
1x revenue
CMP Current Conservative Premium Illustrative
$60-70M $240-280M $360-420M $480-560M
Market capitalisation
----- End of picture text -----

==> picture [348 x 54] intentionally omitted <==

Growth & Outlook

==> picture [960 x 359] intentionally omitted <==

Growth & Outlook

==> picture [529 x 73] intentionally omitted <==

Record H1 performance supports FY26 delivery and earnings momentum

Growth Opportunities

==> picture [50 x 52] intentionally omitted <==

U.S. market opportunity remains significant, with large underdiagnosed population supporting long-term growth in sleep diagnostics

FY26 Target

• Revenue growth of +37% YoY to $70.0M

• EBITDA expansion to $9.0M supported by mix and scale

• Progress toward consistent profitability and continued positive free cash flow

==> picture [50 x 52] intentionally omitted <==

==> picture [50 x 48] intentionally omitted <==

Somfit SaaS scaling driving recurring revenue growth, particularly in home sleep testing

Expanding global footprint across Asia and Europe, with continued penetration into key markets

Short to Medium Term

• Scale Somfit D in the U.S. and expand adoption across sleep clinics and provides

• Convert MEG order pipeline into revenue through installations and delivery

• Drive earnings quality through recurring revenue growth and product mix shift

• Deliver operating leverage through disciplined cost control

==> picture [50 x 49] intentionally omitted <==

==> picture [50 x 50] intentionally omitted <==

==> picture [50 x 51] intentionally omitted <==

MEG pipeline progressing , supporting high-value revenue conversion through FY26–FY27

New product cycle underway, including Somfit D rollout in the U.S.

AI-enabled TCD development enhancing DWL offering and future revenue streams

Long Term

• Scale Somfit platform to capture a meaningful share of the U.S. home sleep testing market (~US$100–200m opportunity)

• Transition to a higher-margin, recurring revenue model , improving visibility and scalability of earnings

• Commercialise Orion LifeSpan MEG as a high-value neurodiagnostic platform with global demand

• Build integrated diagnostic platform across sleep, neuro and remote care

• Expand into adjacent verticals leveraging data, AI and installed base

• Supporting transition to a higher-quality, scalable earnings profile

Disclaimer

==> picture [529 x 73] intentionally omitted <==

This presentation has been prepared by Compumedics Limited (CMP).

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statements. These forward-looking statements have been made based upon CMP’s expectations and beliefs concerning future developments and their potential effect on CMP (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP’s control. No assurance is given that future developments will be in accordance with CMP’s expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.

Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular investment needs.

Thank You

==> picture [348 x 54] intentionally omitted <==

==> picture [529 x 105] intentionally omitted <==

==> picture [432 x 105] intentionally omitted <==